Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Baricitinib may effectively treat oral lichen planus.

Dupilumab may help hair regrowth in some patients with severe atopic dermatitis, but results vary.

An elderly Chinese man lost all his hair after taking a new heart medication.

People with alopecia areata may have a higher risk of blood clots.

Low dose methotrexate does not increase hair fall and may reduce it.

Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.

Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.

Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.

People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.

Personalized medicine is important for treating skin disorders, with new treatments and connections to hormones and genetics being explored.

The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.

Follicular mucinosis can be an early sign of aggressive mycosis fungoides.

GLPLS and LPP are variants of lichen planus.

New targeted immunotherapies are improving treatment for inflammatory skin diseases.

Foam corticosteroid covers as well as traditional forms.

An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.

Stress may contribute to hair loss in alopecia areata by affecting immune responses and cell death in hair follicles.

Cannabinoids like CBD and THC may help treat non-cancer skin diseases, but more research is needed.

Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.

Natural products may help treat skin inflammation from abnormal adrenal hormones.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

Recognizing scalp symptoms in PRP is crucial for proper diagnosis and treatment.

PRO-C22 can help diagnose and monitor the severity of hidradenitis suppurativa.

Cyclosporine may cause hair loss, so patients need monitoring.

Baricitinib successfully treated myasthenia gravis and alopecia in a patient.

Low-dose oral minoxidil is safe for treating children's hair disorders.

Sequential therapy with dupilumab and baricitinib improved hair regrowth and atopic dermatitis in a child without adverse reactions.

Hair loss in Androgenetic Alopecia is caused by genetics, aging, and lifestyle, leading to hair follicle shrinkage and related health risks.